

003\_a

## Laboratory Results

<b>White Blood Cell Count (WBC)</b>	6,000 - 10,000 cells/ $\mu$ L	4,500 - 10,000 cells/ $\mu$ L
<b>Neutrophils</b>	55%	40% - 60%
<b>Lymphocytes</b>	35%	20% - 40%
<b>Monocytes</b>	5%	2% - 8%
<b>Eosinophils</b>	3%	1% - 4%
<b>Basophils</b>	2%	0% - 1%
<b>Hemoglobin (Hgb)</b>	12.0 - 14.5 g/dL	11.5 - 15.5 g/dL
<b>Hematocrit (Hct)</b>	36% - 44%	35% - 45%
<b>Platelet Count</b>	150,000 - 450,000 cells/ $\mu$ L	150,000 - 450,000 cells/ $\mu$ L

## Pathology Report 10/4/24

**Date of Birth:** 7/30/2017

**Date of Procedure:** 10/4/24

**Referring Physician:** Dr. Oncoso

**Clinical History:** B-cell precursor acute lymphoblastic leukemia (B-ALL), post-consolidation phase treatment.

---

**Procedure:** Bone Marrow Biopsy

### Findings:

- **Bone Marrow Cellularity:** Hypercellular (approximately 90% cellularity).
- **Blast Cell Percentage:** Less than 5% blast cells, consistent with clinical remission.

### Flow Cytometry Results:

- **Minimal Residual Disease (MRD) Status:** Positive for minimal residual disease (MRD+).

- **Leukemic Cell Percentage:** 0.05% leukemic cells detected.

**Interpretation:**

The findings indicate the patient is in clinical remission following consolidation treatment; however, the presence of minimal residual disease suggests residual leukemic activity. Continuous monitoring and further therapeutic intervention may be warranted.

## Pathology Report 3/29/24

**Date of Birth:** 7/30/2017

**Date of Procedure:** 03/29/2024

**Referring Physician:** Dr. Oncoso

**Clinical History:** Patient presented with fatigue and recurrent infections. Bone marrow biopsy performed to evaluate for acute lymphoblastic leukemia.

---

**Procedure:** Bone Marrow Biopsy

**Specimen Received:** Bone marrow aspirate and core biopsy.

**Findings:**

- **Bone Marrow Cellularity:** Hypercellular (approximately 90% cellularity).
- **Blast Cell Percentage:** 85% lymphoblasts present in the marrow, confirming the diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL).
- **Differential Cell Count:**
  - Lymphoblasts: 85%
  - Myeloid series: 5%
  - Erythroid series: 5%
  - Other cell types: 5%

**Cytogenetic Analysis:**

- **Cytogenetic Findings:** Philadelphia chromosome-negative (Ph-), confirming the absence of the BCR-ABL fusion gene.

**Interpretation:**

The findings confirm a diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL) characterized by hypercellularity and a high percentage of lymphoblasts. The absence of the Philadelphia chromosome indicates a potentially more favorable prognosis. Further clinical management and monitoring for minimal residual disease are recommended.